All studies
RecruitingPhase I and Phase II (Integrated)- First administration to humansInterventional

A Phase 1/2, Multicenter, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies

This early-stage clinical trial is testing an experimental medicine called pivekimab sunirine (also known as IMGN632). It is designed for adults living with acute myeloid leukaemia (AML) or other blood cancers whose abnormal cells carry a specific marker called CD123. Because this is one of the first times this drug is being tested in humans, the main goal is to find the safest and most effective dose to give through a drip. Doctors also want to learn what side effects occur and whether the treatment can reduce cancer cells in the blood and bone marrow. For some conditions, researchers will also see if the medicine reduces the need for regular blood transfusions. Taking part is voluntary, and participants are closely monitored by hospital specialists throughout the study.

At a glance

Status
Recruiting
Phase
Phase I and Phase II (Integrated)- First administration to humans
Sponsor
AbbVie Deutschland GmbH & Co. KG
Enrolment target
34
Start
05 Jul 2024

What is this study about?

Acute myeloid leukaemia (AML) and related blood conditions are cancers that affect how the bone marrow makes healthy blood cells. In many patients, these cancer cells carry a distinct protein on their surface called CD123. Researchers are actively looking for targeted medicines that can find this specific marker and deliver cancer-fighting treatment directly to the diseased cells, aiming to spare healthy tissues nearby.

This study focuses on an experimental medicine called pivekimab sunirine. It works like a guided missile: it binds to the CD123 protein on the cancer cell and releases a strong therapy inside it to destroy the cell. The trial is divided into two parts. The first part tests gradually increasing doses to determine the safest amount to use. The second part tests that chosen dose in a wider group of patients to evaluate its effectiveness.

During the trial, doctors will track how well the treatment shrinks tumours, clears leukaemia from the bone marrow, and improves blood counts. They will also see whether patients need fewer red blood cell or platelet transfusions. Studies like this are vital for discovering new options for people whose blood cancer has returned or has not responded to standard treatments.

Key takeaways

  • Tests an experimental drug called pivekimab sunirine for CD123-positive blood cancers.
  • Aimed at finding the safest dose and seeing how well it clears cancer cells.
  • Open to adults aged 18 and older whose cancer has returned or resisted standard treatment.
  • Given as an intravenous drip during regular hospital visits.
  • Participation is entirely voluntary, and you can withdraw at any time.

Who may be eligible?

This trial is for adults aged 18 and older who have acute myeloid leukaemia (AML) or other specific blood cancers, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN). To be considered, laboratory tests must show that your cancer cells carry the CD123 protein.

Generally, participants in this type of study have cancer that has either returned after previous treatment (relapsed) or did not improve with standard therapies (refractory). You must also be well enough to carry out daily tasks and have reasonably healthy kidney and liver function so your body can process the medication safely.

You may not be eligible if you have certain other serious health issues, such as active, uncontrolled infections or severe heart problems. A study doctor will review your full medical history and perform health checks to confirm whether joining the trial is safe and suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with acute myeloid leukaemia (AML) or a related blood cancer.
  3. My cancer cells have been confirmed (or can be tested) as CD123-positive.
  4. My cancer has returned or has not responded to prior treatments.
  5. I am well enough to attend frequent hospital visits for treatment and monitoring.
Answer every question to see your result.

What does participation involve?

If you take part, you will receive pivekimab sunirine as an intravenous infusion (a slow drip into a vein) at a hospital clinic. Because this is an early-phase trial, you will need frequent visits, especially during the first few weeks, so the medical team can monitor your health closely. Visits will include blood tests, physical examinations, heart scans (ECGs), and occasional bone marrow biopsies to check how your body and cancer are responding. Treatment is usually given in repeating cycles and can continue as long as it helps your condition and side effects remain manageable. Once treatment ends, the research team will keep in touch through follow-up visits to check on your long-term wellbeing.

Potential risks and benefits

Taking part may help shrink your cancer, improve your symptoms, or lessen your need for blood transfusions, but these benefits cannot be guaranteed. Because this is an experimental drug, there is a risk of side effects. These can range from mild effects like tiredness and nausea to more serious issues like low blood cell counts or infections. Your safety is monitored very carefully, and treatments are available to manage side effects. Joining the study is entirely your choice, and you are free to leave at any time without it affecting your standard NHS care.

Locations (2)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Spain
  • —
    Unverified
    France

Common questions

What is CD123?

CD123 is a specific protein found on the surface of certain blood cancer cells. It acts as a target for the experimental drug being tested in this trial.

Will I receive a dummy drug (placebo)?

No. This is an open-label study, which means every person who takes part receives the active trial medicine.

How is the trial medicine given?

The medicine is given through a drip directly into a vein (intravenously) during visits to the hospital clinic.

How long will I be in the study?

You can stay on the treatment for as long as it continues to help you and does not cause unsafe side effects, followed by a period of regular follow-up checks.

Can I leave the study if I change my mind?

Yes. You have the right to withdraw from the trial at any time. Your normal medical care and relationship with your doctors will not be affected.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Phase 1/2, Multicenter, Open-label Study of IMGN632 Monoth…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.